



MATERIAL SAFETY DATA SHEET

Product Name: Paclitaxel Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address Hospira Inc.
275 North Field Drive
Lake Forest, Illinois USA
60045

Hospira Australia Pty Ltd
1 Lexia Place
Mulgrave VIC 3170
Australia

Emergency Telephone CHEMTREC: North America: 800-424-9300;
International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418

Hospira, Inc., Non-Emergency 224-212-2000

Product Name Paclitaxel Injection, USP

Synonyms Taxol[®]

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name Paclitaxel

Chemical Formula C₄₇H₅₁NO₁₄

Preparation Hazardous ingredients present at less than 1% include citric acid.

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Paclitaxel	~0.65	33069-62-4	DA8340700
Cremophor EL	~57	61791-12-6	GO5661000
Ethyl Alcohol	~42	64-17-5	KQ6300000

3. HAZARD INFORMATION

Carcinogen List

Substance	IARC	NTP	OSHA
Cremophor EL	Not Listed	Not Listed	Not Listed
Ethyl Alcohol	Not Listed	Not Listed	Not Listed
Paclitaxel	Not Listed	Not Listed	Not Listed

Emergency Overview Paclitaxel Injection, USP, contains paclitaxel, a taxane prepared semi-synthetically from a precursor derived from the needles of the European yew. Paclitaxel induces microtubule formation and stabilization of microtubules, thereby disrupting normal cell division. Clinically, paclitaxel is used to treat some types of cancers. In the workplace, this material should be considered a flammable liquid, cytotoxic, neurotoxic, a potential occupational reproductive hazard, harmful to the fetus, a potential human carcinogen, and potentially irritating to the skin, eyes, and respiratory tract. Following an accidental over-exposure, possible target organs may

Product Name: Paclitaxel Injection, USP



include the bone marrow, gastrointestinal system, peripheral nervous system, cardiovascular systems, liver, skin and the fetus.

Occupational Exposure Potential	There are scientific studies that suggest that personnel (e.g. nurses, pharmacists, etc.) who prepare and administer parenteral antineoplastics (e.g. in hospitals) may be at some risk due to potential mutagenicity, teratogenicity, and/or carcinogenicity of these materials if workplace exposures are not properly controlled. The actual risk in the workplace is not known.
Signs and Symptoms	During occupational use, this material should be considered irritating to the skin, eyes and respiratory tract. In clinical use, adverse effects have included myelosuppression, nausea, vomiting and diarrhea, fatigue, hair loss, bradycardia and abnormal ECG, hepatotoxicity, peripheral neuropathy, hair loss, joint and muscle pain, and hypersensitivity reactions.
Medical Conditions Aggravated by Exposure	Pre-existing hypersensitivity to paclitaxel. Pre-existing bone marrow, blood, gastrointestinal, cardiovascular, peripheral nervous system, liver, or skin ailments; or pregnancy.

4. FIRST AID MEASURES

Eye contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	Flashpoint: 13.6°C (56.4°F).
Fire & Explosion Hazard	Flammable liquid. Keep away from flames, sparks, and other sources of ignition.
Extinguishing media	As with any fire, use extinguishing media appropriate for primary cause of fire., For large fires, apply water from as far away as possible; use very large quantities of water applied as a mist or spray., For small fires, use water fog or fire extinguishing media suitable for Class B fires (e.g. dry chemical, carbon dioxide or foam).
Special Fire Fighting Procedures	Firefighters should wear self-contained breathing apparatus. Protective equipment and clothing should be worn to minimize contact with the respiratory tract, skin and eyes.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Isolate area around spill and remove all sources of ignition. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb liquid with suitable material and clean affected area with soap and water. An
-----------------------------------	---

undiluted solution of household bleach may be applied to the spill for ten minutes to inactivate paclitaxel. Absorb the liquid with an inert absorbent material (e.g. absorbent pad). Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling

Paclitaxel is a cytotoxic agent. Appropriate procedures should be implemented during the handling and disposal of cytotoxic antineoplastics agents to minimize potential exposures. Several guidelines on handling cytotoxic antineoplastic agents have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Consult your hygienist or safety professional for your site requirements.

Avoid ingestion, inhalation, skin contact, and eye contact. If handling a powder, precautions may include the use of a containment cabinet during the weighing, reconstitution and/or solubilization of this antineoplastic agent. The use of disposable gloves and respiratory protection is recommended. Proper disposal of contaminated vials, syringes, or other materials may be required when working with this material.

Storage

No special storage is required for hazard control. However, employees should be trained on the proper storage procedures for antineoplastic agents. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.

Special Precautions

Persons with known hypersensitivities to paclitaxel, women who are pregnant, or women who want to become pregnant, should consult a health and/or safety professional prior to handling this material.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Type	Exposure limits			Note
		mg/m ³	ppm	µg/m ³	
Ethyl Alcohol	ACGIH 8 Hr TLV	N/A	1000	N/A	
Ethyl Alcohol	US OSHA 8 Hr PEL	N/A	1000	1900	
Ethyl Alcohol	Australia NOHSC	N/A	1000	N/A	
Cremophor EL	Not Applicable	N/A	N/A	N/A	None Established
Paclitaxel	Not Applicable	N/A	N/A	N/A	None Established

Respiratory protection

Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols or vapors is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (P100 or equivalent) with an organic vapor cartridge is recommended under conditions where airborne aerosol or vapor concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin protection

When handling this material, disposable gloves should be worn at all times. Further, the use of double gloves is recommended. Disposable gloves made from nitrile, neoprene, polyurethane or natural latex generally have low permeability to this material. Persons known

Product Name: Paclitaxel Injection, USP



to be allergic to latex rubber should select a non-latex glove. Gloves should be changed regularly, and removed immediately after known contamination. Care should be taken to minimize inadvertent contamination when removing and/or disposing of gloves.

Eye protection As a minimum, the use of chemical safety goggles is recommended when handling this material.

Engineering Controls When handling, local exhaust ventilation is recommended to minimize employee exposure. The use of an enclosure, such as an approved ventilated cabinet designed to minimize airborne exposures, is recommended.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Liquid
Color	Clear colorless to slightly yellow
Odor	Alcohol
Odor Threshold:	NA
pH:	NA
Melting point/Freezing point:	NA
Initial Boiling Point/Boiling Point Range:	NA
Evaporation Rate:	NA
Flammability (solid, gas):	NA
Upper/Lower Flammability or Explosive Limits:	LEL 3.3% UEL 19% based on ethanol
Vapor Pressure:	NA
Vapor Density:	NA
Specific Gravity:	NA
Solubility:	The active ingredient, paclitaxel, has low solubility in water
Partition coefficient: n-octanol/water:	NA
Auto-ignition temperature:	NA
Decomposition temperature:	NA

10. STABILITY AND REACTIVITY

Reactivity	Not Applicable
Chemical Stability	This product is stable.
Hazardous Reactions	Not Applicable
Conditions to avoid	Heat, flames, sparks or other sources of ignition.
Incompatibilities	Oxidizing agents, acids, and bases. Do not use with PVC materials.
Hazardous decomposition products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx) and nitrogen oxides (NOx).
Hazardous Polymerization	Not anticipated to occur with this material.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity

Not determined for the product formulation. Information for the ingredients is as follows:

Ingredient(s)	Percent	Route	Test Type	Value	Units	Species
Paclitaxel	100	Intravenous	LD50	85	mg/kg	Rat
Paclitaxel	100	Intravenous	LD50	12	mg/kg	Mouse
Paclitaxel	100	Intraperitoneal	LD50	32.5	mg/kg	Rat
Paclitaxel	100	Intraperitoneal	LD50	128	mg/kg	Mouse
Ethyl Alcohol	100	Oral	LD50	3450 – 11,500	mg/kg	Guinea Pig, Rat, Mouse, Dog
Ethyl Alcohol	100	Intravenous	LD50	1973	mg/kg	Mouse
Ethyl Alcohol	100	Inhalation	LC50 (10h)	20,000	ppm	Rat
Ethyl Alcohol	100	Inhalation	LD50 (4h)	39,000	mg/m ³	Mouse
Cremophor EL	100	Oral	LD50	> 6400	mg/kg	Rat
Cremophor EL	100	Dermal	LD50	> 5000	mg/kg	Rat

Aspiration Hazard

None anticipated from normal handling of this product. However, inadvertent inhalation of the product aerosol may produce respiratory irritation.

Dermal Irritation/Corrosion

None anticipated from normal handling of this product. Following inadvertent skin contact, this product may produce irritation with itching and redness. Cremophor EL was non-irritating in a skin irritation study in rabbits. Ethanol may produce mild skin irritation with redness and dryness.

Ocular Irritation/Corrosion

None anticipated from normal handling of this product. Following inadvertent eye contact, this product may produce irritation, redness and discomfort. Exposure to ethanol or Cremophor EL may produce eye irritation. Exposure to ethanol has produced severe eye irritation in studies in animals.

Dermal or Respiratory Sensitization

No data found. In clinical use, anaphylaxis and severe hypersensitivity reactions including dyspnea, hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2-4% of patients receiving paclitaxel. Cremophor EL was non-sensitizing in a sensitization study in guinea pigs.

Reproductive Effects

Administration of paclitaxel prior to and during mating impaired fertility in male and female rats at dosages \leq 1 mg/kg/day. At this dosage, paclitaxel caused reduced fertility and reproductive indices, and increased embryo- and fetotoxicity. Administration of paclitaxel during the period of organogenesis to rabbits at a dosage of 3.0 mg/kg/day caused embryo- and fetotoxicity, as indicated by intrauterine mortality, increased resorptions, and increased fetal deaths. Maternal toxicity was also observed at this dose. No teratogenic effects were noted at a dosage of 1.0 mg/kg/day; the teratogenic potential could not be assessed at higher doses due to extensive fetal mortality. Ethanol has been shown to produce fetotoxicity in the embryo or fetus of laboratory animals. Chronic prenatal exposure to ethanol has been associated with a distinct pattern of congenital malformations that have collectively been termed the "fetal alcohol syndrome". No adverse effects on fertility or fetal development were noted in studies in animals given Cremophor EL.

Product Name: Paclitaxel Injection, USP

Mutagenicity	Paclitaxel was clastogenic in vitro (producing chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice). Paclitaxel was not mutagenic in the Ames test or in the CHO/HGPRT gene mutation assay. No mutagenic effect was found in various tests with bacteria and mammalian cell culture with Cremophor EL; it was not mutagenic in studies with mammals.
Carcinogenicity	The carcinogenic potential of paclitaxel has not been fully evaluated in long-term studies in animals. Cremophor EL was not carcinogenic in chronic dietary studies in animals.
Target Organ Effects	This material should be considered irritating to the skin, eyes and respiratory tract. Following an accidental over-exposure, possible target organs may include the bone marrow, peripheral nervous system, cardiovascular system, gastrointestinal system, liver, skin and the fetus.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for the product. Information for ingredients is provided below: LC50 > 0.74 mg/L in Daphnia for paclitaxel IC50 > 1000 mg/L for inhibition of respiration in activated sludge for paclitaxel. LC50(24 hr) = 12,900 - 15,300 mg/L in rainbow trout for ethanol LC50 (24 hr) = 11,200 mg/L in fingerling trout for ethanol LC50(48 hr) = 9,268 - 14,221 mg/L in Daphnia magna for ethanol EC50 = 9310 mg/L in Chlorella pyrenoidosa (green algae) for ethanol
Persistence/Biodegradability	Not determined for the product. Information for ingredients is provided below: Paclitaxel undergoes anaerobic degradation. Ethanol was reported to be degraded between 45% and 74% in five days in two aqueous biodegradation assays.
Bioaccumulation	Not determined for the product. Information for ingredients is provided below: Because of its low octanol:water partition coefficient, ethanol is not anticipated to bioaccumulate.
Mobility in Soil	Not Applicable

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements. Product is classified as hazardous waste (D001) based on flashpoint testing.
Container Handling and Disposal	Dispose of containers and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

ADR/ADG/ DOT STATUS:	Regulated
Proper Shipping Name:	Ethanol Solution
Hazard Class:	3

Product Name: Paclitaxel Injection, USP

UN number: UN1170
Packing group: II
Reportable Quantity: N/A

IMDG STATUS: Regulated
Proper Shipping Name: Ethanol Solution
Hazard Class: 3
UN number: UN1170
Packing group: II
Reportable Quantity: N/A

ICAO/IATA STATUS: Regulated
Proper Shipping Name: Ethanol Solution
Hazard Class: 3
UN number: UN1170
Packing group: II
Reportable Quantity: N/A

Transport Comments: None

15. REGULATORY INFORMATION
USA Regulations

Substance	TSCA Status	CERCLA Status	SARA 302 Status	SARA 313 Status	PROP 65 Status
Cremophor EL	Listed	Not Listed	Not Listed	Not Listed	Not Listed
Ethyl Alcohol	Listed	Not Listed	Not Listed	Not Listed	Not Listed
Paclitaxel	Not Listed	Not Listed	Not Listed	Not Listed	Listed

RCRA Status Classified as D001 hazardous waste based on ignitability.

U.S. OSHA Classification
 Possible Carcinogen
 Target Organ Toxin
 Reproductive Toxin
 Flammable Liquid
 Possible Irritant

GHS Classification
 *In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user:

Hazard Class Not Applicable

Hazard Category Not Applicable

Signal Word Not Applicable

Symbol Not Applicable

Prevention P260 - Do not breathe dust/fume/gas/mist/vapors/spray.

Hazard Statement Not Applicable

Response: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling.

Product Name: Paclitaxel Injection, USP



Get medical attention if you feel unwell.

EU Classification*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance Paclitaxel

Classification(s): Not Applicable

Symbol: Not Applicable

Indication of Danger: Not Applicable

Risk Phrases: Not Applicable

Safety Phrases: S23 - Do not breathe vapor.
S24 - Avoid contact with skin.
S25 - Avoid contact with eyes.
S37/39 - Wear suitable gloves and eye/face protection.

16. OTHER INFORMATION:

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD ₅₀	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS

Date Prepared: 10/19/2012

Obsolete Date: 10/31/2011

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.